Evidence map›Paper›PMID 41886248›Full record

ArticleChemMedChem2026

Repurposing of Inhibitors of Plasmodial Aspartate Transcarbamoylase Toward Trypanosoma Cruzi.

Siyao Chen, Monica Cal, Queenie Mondile, Rick Oerlemans, Mukim Mayur Shashikant, Alexander S S Dömling, Özlem Tastan Bishop, Pascal Mäser, Matthew R Groves

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Siyao ChenDepartment of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands.
Monica CalDepartment Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Queenie MondileUnit in Bioinformatics (RUBi), Department of Biochemistry, Microbiology and Biochemistry, Rhodes University, Makhanda, South Africa.
Rick OerlemansDepartment of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands.
Mukim Mayur ShashikantInnovative Chemistry Group, Institute for Molecular and Translational Medicine (IMTM) and Czech Advanced Technology and Research Institute (CATRIN) Univerzita Palackého v Olomouci, Olomouc, Czechia.
Alexander S S DömlingInnovative Chemistry Group, Institute for Molecular and Translational Medicine (IMTM) and Czech Advanced Technology and Research Institute (CATRIN) Univerzita Palackého v Olomouci, Olomouc, Czechia.
Özlem Tastan BishopUnit in Bioinformatics (RUBi), Department of Biochemistry, Microbiology and Biochemistry, Rhodes University, Makhanda, South Africa.
Pascal MäserDepartment Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil, Switzerland.
Matthew R GrovesDepartment of Chemical and Pharmaceutical Biology, University of Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0001-9859-5177

Funding

China Sponsorship CouncilH2020 Marie Skłodowska-Curie Actions 860816
6 · The paper itself

Abstract

Aspartate transcarbamoylase (ATC) catalyzes the committed and rate-limiting step in the pyrimidine de novo biosynthesis pathway. While previously suggested to be a potential target for antimalarial, antitubercular, and antioncologic drug discovery, we hypothesized that an existing compound library of ATC inhibitors designed from one scaffold by fragment screening against Plamodium falciparum ATC (PfATC) may also contain inhibitors of Trypanosoma cruzi ATC (TcATC). In this manuscript, we screened the 70-member library at 35 μM against 50 nM TcATC, and in these initial experiments, 34 compounds showed over 90% inhibition. Of the 34 compounds, 5 compounds demonstrated IC

Indexed as

Aspartate CarbamoyltransferaseDrug RepositioningEnzyme InhibitorsTrypanosoma cruziDose-Response Relationship, DrugModels, MolecularMolecular StructureStructure-Activity RelationshipAspartate CarbamoyltransferaseEnzyme Inhibitorsaspartate transcarbamoylasechagas diseaseinhibitormolecular modelingpyrimidine biosynthesistrypanosoma cruzi

Identifiers

PMID41886248
PMCPMC13020662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.